Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes
Source: Henriksen JN, et al. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. Clinical Genitourinary Cancer, February 2020. DOI: 10.1016/j.clgc.2019.09.013
Please sign in or register for FREE
Sign in to OnMedica
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date
See what other members have to say:
"Very useful, I have filled many gaps and gained practical knowledge."
"I feel now more confident in diagnosing the presented conditions. Really it is one of the best learning activities I have completed recently."
No comments yet.